Gilead Sciences, through its Kite Pharma subsidiary, commands the largest share of the global CAR-T cell therapy market with approximately $1.8 billion in 2025 CGT product sales.

Gilead Sciences, through its Kite Pharma subsidiary, commands the largest share of the global CAR-T cell therapy market with approximately $1.8 billion in 2025 CGT product sales. While Gilead's overall revenue reached $29.4 billion, its cell therapy portfolio represents an increasingly important growth driver. Kite's manufacturing leadership and deep clinical expertise in lymphoma have established Gilead as the dominant force in commercial CAR-T therapy.

Strengths: Parent company provides substantial financial resources and global commercial infrastructure; Kite's internal manufacturing network remains the industry gold standard; deep clinical data package supporting Yescarta across multiple lymphoma subtypes; expanding Tecartus indications in ALL and MCL; total company revenue of $29.4B providing stability and investment capacity.

Weaknesses: Cell therapy franchise represents only ~6% of total company revenue, limiting strategic prioritization; Kymriah competition from Novartis/BMS pressuring Yescarta market share; Q4 2025 cell therapy sales declining 6% year-over-year; corporate complexity as large diversified pharmaceutical company.